Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Age 18-55 years.~ 2. For healthy volunteers: in general good health, without significant medical illness, physical exam findings, or significant laboratory abnormalities as determined by the investigator.~ 3. For participants with AD-HIES: confirmation of diagnosis with a STAT3 mutation.~ 4. Participants who can get pregnant must be willing to use an acceptable form of contraception for the duration of participation and have a negative pregnancy test at screening.~ 5. Agree to allow storage of biological samples for future research.~EXCLUSION CRITERIA:~1. Has a history of allergic response or other serious reaction to aluminum and/or yeast products.~2. Has a history of clinically significant allergy including anaphylaxis or other serious reaction to food, vaccines, or other drugs, that in the opinion of the investigator, might put the participant at undue risk.~3. Has an active infection (such as S aureus abscess, pneumonia, acute Candida mucocutaneous infection). Baseline state of chronic infections will be considered by the PI (eg, chronic Pseudomonas infection in lung).~4. Has an active infection with hepatitis B, hepatitis C, or HIV.~5. Has received or is planning to receive any investigational drug, investigational vaccine, or investigational device within four weeks prior to vaccination, or at any other time during their participation in the study.~6. Has received or is planning to receive any other live vaccine within three weeks before vaccination or for three weeks after vaccination.~7. Self-reported current alcohol abuse or addiction.~8. Self-reported current illicit drug abuse or addiction, or drug screen positive for illicit drugs.~9. Current or planned use, within 3 weeks before vaccination, of any medications or treatments that may alter immune responses to the study vaccine (eg, immunosuppressive medications including systemic corticosteroids, cyclosporine, tacrolimus, cytotoxic drugs, Bacillus Calmette-Guerin, monoclonal antibodies, or radiation therapy). Topical, intranasal, or inhaled immunosuppressants such as corticosteroids will be allowed.~10. Current or planned use within 2 weeks before vaccination of immune globulin replacement.~11. Has any of the following laboratory abnormalities at the screening visit:~    1. Alanine transaminase (ALT), aspartate transaminase (AST), and/or alkaline~       phosphatase (ALP) \> 1.5 times the upper limit of normal (ULN).~   2. Total bilirubin level \> 1.5 times the ULN~   3. Serum creatinine level \> 1.5 times the ULN~   4. Absolute neutrophil count \< 750 cells/microliter~   5. Hemoglobin \< 9 mg/dL~   6. Platelet count \< 100,000~12. Refusal or inability to comply with study procedures to the extent that it is potentially harmful to the participant or to the integrity of the study data.~13. Has donated blood/plasma within four weeks before vaccination.~14. Is pregnant or breastfeeding, or intends to become pregnant over the course of the study.~15. Is unable to commit to the follow-up visits and or has unreliable access to a telephone for follow-up contacts, either by self-admission (self-reporting) or in the opinion of the investigator.~16. Any other condition the investigator believes would interfere with the participant s ability to provide informed consent, comply with study instructions, or that might confound the interpretation of the study results or put the participant at undue risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- NDV 3A vaccine (Type: EXPERIMENTAL): Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).